am 580 has been researched along with Virus Diseases in 1 studies
Am 580: a selctive retinoic acid receptor (alpha) agonist; structure given in first source
4-{[(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)carbonyl]amino}benzoic acid : An amidobenzoic acid obtained by formal condensation of the carboxy group of (5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)benzoic acid with the anilino group of 4-aminobenzoic acid. A selective RARalpha agonist.
Virus Diseases: A general term for diseases caused by viruses.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yuan, S | 1 |
| Chu, H | 1 |
| Chan, JF | 1 |
| Ye, ZW | 1 |
| Wen, L | 1 |
| Yan, B | 1 |
| Lai, PM | 1 |
| Tee, KM | 1 |
| Huang, J | 1 |
| Chen, D | 1 |
| Li, C | 1 |
| Zhao, X | 1 |
| Yang, D | 1 |
| Chiu, MC | 1 |
| Yip, C | 1 |
| Poon, VK | 1 |
| Chan, CC | 1 |
| Sze, KH | 1 |
| Zhou, J | 1 |
| Chan, IH | 1 |
| Kok, KH | 1 |
| To, KK | 1 |
| Kao, RY | 1 |
| Lau, JY | 1 |
| Jin, DY | 1 |
| Perlman, S | 1 |
| Yuen, KY | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Study of a 10-days Fenofibrate Treatment, or Until Discharge From Hospital, Among COVID-19 Infected Patients Requiring Hospitalization[NCT04661930] | Phase 3 | 55 participants (Anticipated) | Interventional | 2021-01-01 | Recruiting | ||
| Modulating Endoplasmic Reticulum Stress as a Prophylactic Approach Against Symptomatic Viral Infection[NCT04267809] | Phase 2 | 44 participants (Anticipated) | Interventional | 2021-10-22 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 other study available for am 580 and Virus Diseases
| Article | Year |
|---|---|
SREBP-dependent lipidomic reprogramming as a broad-spectrum antiviral target.
Topics: Antiviral Agents; Benzoates; Biosynthetic Pathways; Influenza A virus; Lipid Metabolism; Lipids; Mid | 2019 |
SREBP-dependent lipidomic reprogramming as a broad-spectrum antiviral target.
Topics: Antiviral Agents; Benzoates; Biosynthetic Pathways; Influenza A virus; Lipid Metabolism; Lipids; Mid | 2019 |
SREBP-dependent lipidomic reprogramming as a broad-spectrum antiviral target.
Topics: Antiviral Agents; Benzoates; Biosynthetic Pathways; Influenza A virus; Lipid Metabolism; Lipids; Mid | 2019 |
SREBP-dependent lipidomic reprogramming as a broad-spectrum antiviral target.
Topics: Antiviral Agents; Benzoates; Biosynthetic Pathways; Influenza A virus; Lipid Metabolism; Lipids; Mid | 2019 |